A Clinical Study Evaluating Licaminlimab for Dry Eye Disease (NCT07548632) | Clinical Trial Compass
RecruitingPhase 2/3
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
United States160 participantsStarted 2026-04-16
Plain-language summary
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Physician diagnosis of Dry Eye Disease in the past 6 months
* Use of over-the-counter tears
* Must agree to genotype testing
Key Exclusion Criteria:
\- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is specifically for people with a particular TNFR1 genotype — do I know my genotype, and is there a way to test for it to see if I'd even be eligible for this study?
2Since this is a Phase 2/3 trial for licaminlimab, what do we know so far about its safety profile, and what risks might come with targeting the TNFR1 pathway in the eyes compared to dry eye treatments I'm already familiar with?
3The trial measures change in ocular discomfort at Day 29, which is a relatively short window — does that timeline tell us much about whether this treatment could work long-term, and would I need to keep participating beyond that point?
4Given that this trial is still recruiting and licaminlimab isn't yet approved for dry eye disease, would you recommend I try existing standard treatments first, or is there a reason it might make sense to discuss this study now given where I am in my diagnosis?
5What would participating in this trial actually look like day-to-day for me — how many visits, how is the drug administered, and are there aspects of the study's demands that might be hard to fit around my regular life?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from baseline in global ocular discomfort severity score at Day 29 in participants with DED and specific TNFR1 genotype